de Castro, Tiago and Welland, Sabrina and Jochheim, Leonie and Leyh, Cathrine and Shmanko, Kateryna and Finkelmeier, Fabian and Jeliazkova, Petia and Jefremow, Andre and Gonzalez-Carmona, Maria A. and Kandulski, Arne and Roessler, Daniel and Ben Khaled, Najib and Enssle, Stefan and Venerito, Marino and Fruendt, Thorben W. and Schultheiss, Michael and Djanani, Angela and Pangerl, Maria and Maieron, Andreas and Wirth, Thomas C. and Marquardt, Jens U. and Greil, Richard and Fricke, Christina and Guenther, Rainer and Schmiderer, Andreas and Bettinger, Dominik and Wege, Henning and Scheiner, Bernhard and Mueller, Martina and Strassburg, Christian P. and Siebler, Juergen and Ehmer, Ursula and Waidmann, Oliver and Weinmann, Arndt and Pinter, Matthias and Lange, Christian M. and Saborowski, Anna and Vogel, Arndt (2024) Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort. HEPATOLOGY COMMUNICATIONS, 8 (11): e0562. ISSN , 2471-254X
Full text not available from this repository. (Request a copy)Abstract
Background:Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use in first-line treatment for HCC. This study aims to compare the real-world effectiveness of LEN to atezolizumab/bevacizumab (AZ/BV).Methods:A retrospective analysis was conducted to evaluate the effectiveness and safety of frontline AZ/BV or LEN therapy in patients with advanced HCC across 18 university hospitals in Europe.Results:The study included 412 patients (AZ/BV: n=207; LEN: n=205). Baseline characteristics were comparable between the 2 treatment groups. However, patients treated with AZ/BV had a significantly longer median progression-free survival compared to those receiving LEN. The risk of hepatic decompensation was significantly higher in patients with impaired baseline liver function (albumin-bilirubin [ALBI] grade 2) treated with AZ/BV compared to those with preserved liver function. Patients with alcohol-associated liver disease had poorer baseline liver function compared to other etiologies and exhibited a worse outcome under AZ/BV.Conclusions:In this real-world cohort, survival rates were similar between patients treated with LEN and those treated with AZ/BV, confirming that both are viable first-line options for HCC. The increased risk of hepatic decompensation in patients treated with AZ/BV who have impaired baseline liver function underscores the need for careful monitoring. Future trials should aim to distinguish more clearly between metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PLUS BEVACIZUMAB; SAFETY; albumin-bilirubin grade; hepatic dysfunction; immunotherapy; liver cancer; tyrosine kinase inhibitor |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Aug 2025 08:41 |
| Last Modified: | 18 Aug 2025 08:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65620 |
Actions (login required)
 |
View Item |
